Syncona Limited Issues 9,330 New Shares Under Long-Term Incentive Plan at £1.070 Each

Syncona’s Role as a Life Science Investor and Strategic Use of Incentive Schemes

As a leading life science investor, Syncona Limited operates within the healthcare investment arena where fostering long-term value and retaining talent are key strategic goals. The issuance of shares under its long-term incentive scheme exemplifies a common practice among investment firms to align employee and management interests with shareholder returns over extended periods. In the competitive life sciences investment market, access to specialized investment professionals and scientific expertise is vital for identifying and supporting promising healthcare ventures.

Incentive schemes in this sector serve multiple strategic purposes beyond compensation, including encouraging long-term retention by linking share realisations to continued employment and performance criteria. Syncona’s scheme calculates payouts based on defined valuation methods, here using the closing mid-market share price on a specified date, ensuring transparency and consistency for participants. The relatively small issuance—9,330 shares representing 0.002% of existing shares—indicates a carefully managed scheme designed to reward participants without significantly diluting shareholder value.

Share Pricing and Valuation as of 22 July 2026

The new ordinary shares were issued at A31.070 each, reflecting the closing mid-market price on 22 July 2026. This pricing approach provides an objective and transparent valuation benchmark for scheme participants, consistent with standard equity incentive practices. It allows all stakeholders to verify the price independently and understand the balance Syncona maintains between employee incentives and shareholder interests.

The A31.070 price reflects market conditions and investor sentiment on that date. While subsequent trading prices after the shares’ admission on 24 July 2026 may vary, the announcement does not forecast trading activity or price changes. Given the modest scale of the issuance, any immediate impact on trading patterns is expected to be minimal, though investors may monitor the stock following admission.

Pari Passu Ranking and Shareholder Rights of New Shares

The 9,330 newly issued shares will rank pari passu with existing ordinary shares, meaning they carry identical voting and economic rights without any preferential or subordinate features. This ensures existing shareholders that the incentive scheme does not create a separate class of shares and maintains equality in dividends, voting, and participation in future corporate actions.

This equal ranking aligns with best corporate governance practices and provides transparency regarding the capital structure. Although the issuance is a minor addition—0.002% of existing shares excluding treasury holdings—it confirms that the scheme operates under controlled parameters to protect shareholder interests. The announcement does not specify the total number of issued shares, so investors should consult Syncona’s latest regulatory filings for full share capital details.

One-Year Transfer Restriction and Lock-In Period for Participants

Shares issued under the scheme are subject to a one-year transfer restriction post-realisation, preventing recipients from selling or transferring their shares during this period. This lock-in mechanism reinforces alignment between participant interests and long-term shareholder value, discouraging immediate monetisation and potential short-term selling pressure.

Such transfer restrictions are common in equity incentive schemes within investment sectors focused on long-term value creation and shareholder register stability. For Syncona shareholders, this ensures scheme participants maintain a vested interest in the company’s future performance. The uniform application of this restriction reduces risks of concentrated insider selling and supports market stability.

FCA Approval and Official List Admission Timeline

Syncona has applied to the Financial Conduct Authority for admission of the new shares to the Official List and concurrently to the London Stock Exchange for trading admission. Trading is expected to commence on 24 July 2026, the business day following the announcement on 23 July 2026. This swift timeline is typical for routine share issuances under pre-approved incentive schemes, with streamlined regulatory processes given the limited scale and predictable nature of the issuance.

Official List admission ensures all company shares, including those issued under the scheme, are subject to the highest UK listing standards and disclosure requirements, preserving register integrity and consistent shareholder treatment. Investors should update their records accordingly to reflect the new shares once trading begins.

Dilution Scale and Impact on Share Capital

The issuance of 9,330 shares represents approximately 0.002% dilution of Syncona’s existing issued ordinary shares excluding treasury shares. This minimal increase highlights the company’s conservative approach to managing dilution from incentive scheme realisations. It suggests a strategy of frequent, small-scale issuances rather than large, infrequent tranches, or limited participant realisations during this cycle.

While the announcement does not disclose the total number of scheme participants, aggregate holdings, or realisation frequency, the small issuance size indicates that ongoing dilution from the scheme is unlikely to materially affect Syncona’s long-term capital structure.

Syncona’s Position in the Competitive Life Sciences Investment Sector

Operating as a leading life science investor, Syncona participates in a specialized investment space characterized by significant capital commitments, long investment horizons, and reliance on scientific and commercial expertise. The sector includes venture capital, growth equity, and strategic acquisitions within healthcare, biotech, and medical device companies. Success requires access to specialized talent with scientific backgrounds and strong industry networks.

Equity incentive schemes are vital for retaining experienced professionals over multi-year investment cycles. Unlike some investment sectors with fixed fund periods, life science investors like Syncona benefit from permanent capital structures and long-term employee retention mechanisms. The transparent, market-based pricing of incentive shares further demonstrates Syncona’s commitment to high governance and professional standards.

Treasury Shares and Share Count Clarifications

The announcement’s reference to "existing issued ordinary shares, excluding shares held in treasury" is an important technical detail. Treasury shares are previously issued shares repurchased and held by the company, which do not carry voting rights or dividend entitlements unless reissued. Excluding treasury shares from dilution calculations aligns with UK market conventions by focusing on actively trading shares.

This implies Syncona holds a material treasury share balance, though the exact amount is undisclosed. Investors should consult regulatory filings or the company website for comprehensive share register information, which is essential for accurately assessing ownership stakes and modelling potential dilution from future incentive scheme realisations.

Regulatory Disclosure and Corporate Governance Compliance

This share issuance disclosure via the Regulatory News Service complies with the Financial Conduct Authority’s Listing Rules and Disclosure and Transparency Rules. It includes all material information such as share quantity, pricing method, pari passu ranking, transfer restrictions, and admission timelines. Disclosure of the one-year transfer restriction underscores Syncona’s commitment to transparent communication regarding share terms.

Syncona’s timely and detailed disclosure exemplifies best practices in investor relations, ensuring market participants have full visibility of share capital changes. Contact details for investor relations and the company website www.synconaltd.com provide channels for further information and updates. The announcement’s timing, with trading commencing the next business day, allows investors to adjust portfolios ahead of the new shares’ admission.